Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Pipeline Review, H2 2017 - Product Image

Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Pipeline Review, H2 2017

  • ID: 4384105
  • Report
  • 98 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AbbVie Inc
  • AstraZeneca Plc
  • Celgene Corp
  • Genfit SA
  • Lycera Corp
  • Pfizer Inc
  • MORE
Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Pipeline Review, H2 2017

Summary

Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) pipeline Target constitutes close to 39 molecules. Out of which approximately 36 molecules are developed by companies and remaining by the universities/institutes. The latest report Nuclear Receptor ROR Gamma - Pipeline Review, H2 2017, outlays comprehensive information on the Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - RAR-related orphan receptor gamma (ROR?) is a protein encoded by the RORC gene. ROR? is member of the nuclear receptor family of transcription factors. It exist in two isoforms ROR? and ROR?t. ROR? is expressed in many tissues, including thymus, lung, liver, kidney, muscle, and brown fat. R OR?t, appears to be highly restricted to the thymus. ROR? isoform is involved in the regulation of circadian rhythms and ROR?t plays an important regulatory role in thymopoiesis and in inhibiting apoptosis. The molecules developed by companies in Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 4, 20, 8 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 3 molecules, respectively. Report covers products from therapy areas Immunology, Central Nervous System, Gastrointestinal, Oncology, Musculoskeletal Disorders, Respiratory, Dermatology, Metabolic Disorders and Other Diseases which include indications Psoriasis, Rheumatoid Arthritis, Autoimmune Disorders, Inflammation, Multiple Sclerosis, Plaque Psoriasis (Psoriasis Vulgaris), Psoriatic Arthritis, Inflammatory Bowel Disease, Non-Alcoholic Steatohepatitis (NASH), Allergies, Ankylosing Spondylitis (Bekhterev's Disease), Asthma, Axial Spondyloarthritis, Breast Cancer, Chronic Obstructive Pulmonary Disease (COPD), Encephalomyelitis, Metastatic Cancer, Neuromyelitis Optica (Devic’s Syndrome), Orphan Diseases, Skin Inflammation, Solid Tumor, Systemic Lupus Erythematosus and Type 1 Diabetes (Juvenile Diabetes).

Furthermore, this report also reviews key players involved in Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC)
  • The report reviews Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) targeted therapeutics
Reasons to Buy:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AbbVie Inc
  • AstraZeneca Plc
  • Celgene Corp
  • Genfit SA
  • Lycera Corp
  • Pfizer Inc
  • MORE
Introduction

Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Overview

Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Companies Involved in Therapeutics Development

AbbVie Inc

Advinus Therapeutics Ltd

Allergan Plc

Arrien Pharmaceuticals LLC

AstraZeneca Plc

Aurigene Discovery Technologies Ltd

Beijing Hanmi Pharmaceutical Co Ltd

Biogen Inc

Brickell Biotech Inc

Bristol-Myers Squibb Company

Celgene Corp

Eli Lilly and Company

Genentech Inc

Genfit SA

GlaxoSmithKline Plc

Glenmark Pharmaceuticals Ltd

Lead Pharma Holding BV

Lycera Corp

Maruho Co Ltd

Nuevolution AB

Orphagen Pharmaceuticals Inc

Pfizer Inc

Phenex Pharmaceuticals AG

Reata Pharmaceuticals Inc

Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Drug Profiles

ABBV-553 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ARN-6039 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AZD-0284 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BBI-6000 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GRC-39815 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GSK-2981278 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IMU-366 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INV-17 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INV-71 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JNJ-3534 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JTE-451 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LYC-55716 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LYC-56056 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize RAR-Related Orphan Receptor Gamma for Psoriasis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize ROR-Gamma for Inflammation and Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize ROR-Gamma for Multiple Sclerosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize ROR-Gamma for Psoriasis, Psoriatic Arthritis and Axial Spondyloarthritis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit ROR Gamma for Autoimmune Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit ROR-Gamma T for Autoimmune Disorders and Inflammation - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Target ROR Gamma for Autoimmune Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize RAR-Related Orphan Receptor Gamma for Inflammatory Bowel Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize ROR gamma for Breast Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize ROR-Gamma for Autoimmune Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize ROR-Gamma for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize ROR-Gamma for Autoimmune Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize RORc for Autoimmune Diseases and Inflammation - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize RORC for Immunology, Multiple Sclerosis and Non-Alcoholic Steatohepatitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize RORC for Immunology, Multiple Sclerosis, Non-Alcoholic Steatohepatitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize RORgamma for Rheumatoid Arthritis and Psoriatic Arthritis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit ROR gamma-t for Autoimmune Diseases - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit ROR Gamma-t for Multiple Sclerosis and Rheumatoid Arthritis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit RORC for Inflammation - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SR-1001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SR-2211 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TGFTX-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TMP-778 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VPR-66 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VTP-43742 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VTP-45489 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Dormant Products

Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Discontinued Products

Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Product Development Milestones

Featured News & Press Releases

Jul 10, 2017: Phenex announces milestone payment from Janssen for the entry of RORgt inhibitor into Phase I

Jan 04, 2017: Lycera Announces Initiation of Phase 1/2a Study ARGON of Immuno-Oncology Candidate LYC-55716 in Patients with Advanced Solid Tumors

Nov 04, 2016: Lycera Announces Publication of Immuno-Oncology Research, Demonstrating Differentiated Mechanism of RORgamma Agonists

Sep 26, 2016: GENFIT: Successful identification of RORt inverse agonists as candidates for regulatory pre-IND studies

Aug 01, 2016: Arrien Pharmaceuticals Provides Update on ARN-6039

Jun 06, 2016: Vitae Pharmaceuticals Announces Appointment of Carole Sable, M.D., as Chief Medical Officer

Jun 03, 2016: Arrien Pharmaceuticals Initiated Phase I Clinical Trials of ARN-6039 as a New Agent for Treatment of Multiple Sclerosis

May 16, 2016: Arrien Pharmaceuticals Initiates Phase I Clinical trials of ARN-6039

May 09, 2016: Arrien Pharmaceuticals to Initiate the Phase I Clinical trials of Autoimmune Drug

Apr 29, 2016: Arrien Pharmaceuticals Announces FDA Accepts IND Application For ARN-6039

Apr 19, 2016: Lycera Announces Progress in Immuno-Oncology Program Presented at the 2016 American Association for Cancer Research Annual Meeting

Mar 16, 2016: Vitae Pharmaceuticals Achieves Proof-of-Concept with First-in-Class RORyt Inhibitor in Moderate to Severe Psoriasis

Dec 17, 2015: Phenex reaches milestone in collaboration with Janssen

Nov 18, 2015: Vitae Pharmaceuticals Announces Positive Top-Line Results From a Phase 1 Multiple Ascending Dose Trial of VTP-43742

Nov 03, 2015: Lycera Announces Progress in Immuno-Oncology Program to be Presented at Society for Immunotherapy of Cancer (SITC) 2015 Annual Meeting

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H2

Number of Products under Development by Therapy Areas, H2

Number of Products under Development by Indications, H2

Number of Products under Development by Indications, H2 2017 (Contd..1), H2

Number of Products under Development by Companies, H2

Number of Products under Development by Companies, H2 2017 (Contd..1)

Products under Development by Companies, H2

Products under Development by Companies, H2 2017 (Contd..1), H2

Products under Development by Companies, H2 2017 (Contd..2), H2

Products under Development by Companies, H2 2017 (Contd..3), H2

Number of Products under Investigation by Universities/Institutes, H2

Products under Investigation by Universities/Institutes, H2

Number of Products by Stage and Mechanism of Actions, H2

Number of Products by Stage and Route of Administration, H2

Number of Products by Stage and Molecule Type, H2

Pipeline by AbbVie Inc, H2

Pipeline by Advinus Therapeutics Ltd, H2

Pipeline by Allergan Plc, H2

Pipeline by Arrien Pharmaceuticals LLC, H2

Pipeline by AstraZeneca Plc, H2

Pipeline by Aurigene Discovery Technologies Ltd, H2

Pipeline by Beijing Hanmi Pharmaceutical Co Ltd, H2

Pipeline by Biogen Inc, H2

Pipeline by Brickell Biotech Inc, H2

Pipeline by Bristol-Myers Squibb Company, H2

Pipeline by Celgene Corp, H2

Pipeline by Eli Lilly and Company, H2

Pipeline by Genentech Inc, H2

Pipeline by Genfit SA, H2

Pipeline by GlaxoSmithKline Plc, H2

Pipeline by Glenmark Pharmaceuticals Ltd, H2

Pipeline by Lead Pharma Holding BV, H2

Pipeline by Lycera Corp, H2

Pipeline by Maruho Co Ltd, H2

Pipeline by Nuevolution AB, H2

Pipeline by Orphagen Pharmaceuticals Inc, H2

Pipeline by Pfizer Inc, H2

Pipeline by Phenex Pharmaceuticals AG, H2

Pipeline by Reata Pharmaceuticals Inc, H2

Dormant Projects, H2

Discontinued Products, H2

List of Figures

Number of Products under Development by Stage of Development, H2

Number of Products under Development by Therapy Areas, H2

Number of Products under Development by Top 10 Indications, H2

Number of Products by Mechanism of Actions, H2

Number of Products by Stage and Mechanism of Actions, H2

Number of Products by Routes of Administration, H2

Number of Products by Stage and Routes of Administration, H2

Number of Products by Stage and Molecule Type, H
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • AbbVie Inc
  • Advinus Therapeutics Ltd
  • Allergan Plc
  • Arrien Pharmaceuticals LLC
  • AstraZeneca Plc
  • Aurigene Discovery Technologies Ltd
  • Beijing Hanmi Pharmaceutical Co Ltd
  • Biogen Inc
  • Brickell Biotech Inc
  • Bristol-Myers Squibb Company
  • Celgene Corp
  • Eli Lilly and Company
  • Genentech Inc
  • Genfit SA
  • GlaxoSmithKline Plc
  • Glenmark Pharmaceuticals Ltd
  • Lead Pharma Holding BV
  • Lycera Corp
  • Maruho Co Ltd
  • Nuevolution AB
  • Orphagen Pharmaceuticals Inc
  • Pfizer Inc
  • Phenex Pharmaceuticals AG
  • Reata Pharmaceuticals Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll